Biomarker Research | |
Advances of mRNA vaccine in tumor: a maze of opportunities and challenges | |
Review | |
Yuan Yuan1  Fan Gao1  Xingxing He2  Ying Chang3  Qiu Zhao3  | |
[1] Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, China;Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, China;Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;Hubei Clinical Center and Key Laboratory of Intestinal and Colorectal Diseases, Wuhan, China;Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, China;Hubei Clinical Center and Key Laboratory of Intestinal and Colorectal Diseases, Wuhan, China; | |
关键词: mRNA vaccine; Tumor antigens; Algorithmic prediction; Sequence optimization; Adjuvants; mRNA delivery; Tumor immunotherapy; | |
DOI : 10.1186/s40364-023-00449-w | |
received in 2022-11-03, accepted in 2023-01-10, 发布年份 2023 | |
来源: Springer | |
【 摘 要 】
High-frequency mutations in tumor genomes could be exploited as an asset for developing tumor vaccines. In recent years, with the tremendous breakthrough in genomics, intelligence algorithm, and in-depth insight of tumor immunology, it has become possible to rapidly target genomic alterations in tumor cell and rationally select vaccine targets. Among a variety of candidate vaccine platforms, the early application of mRNA was limited by instability low efficiency and excessive immunogenicity until the successful development of mRNA vaccines against SARS-COV-2 broken of technical bottleneck in vaccine preparation, allowing tumor mRNA vaccines to be prepared rapidly in an economical way with good performance of stability and efficiency. In this review, we systematically summarized the classification and characteristics of tumor antigens, the general process and methods for screening neoantigens, the strategies of vaccine preparations and advances in clinical trials, as well as presented the main challenges in the current mRNA tumor vaccine development.
【 授权许可】
CC BY
© The Author(s) 2023
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202305113717351ZK.pdf | 2311KB | download | |
Fig. 5 | 2113KB | Image | download |
Fig. 48 | 812KB | Image | download |
Fig. 8 | 299KB | Image | download |
Fig. 11 | 165KB | Image | download |
【 图 表 】
Fig. 11
Fig. 8
Fig. 48
Fig. 5
【 参考文献 】
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]
- [15]
- [16]
- [17]
- [18]
- [19]
- [20]
- [21]
- [22]
- [23]
- [24]
- [25]
- [26]
- [27]
- [28]
- [29]
- [30]
- [31]
- [32]
- [33]
- [34]
- [35]
- [36]
- [37]
- [38]
- [39]
- [40]
- [41]
- [42]
- [43]
- [44]
- [45]
- [46]
- [47]
- [48]
- [49]
- [50]
- [51]
- [52]
- [53]
- [54]
- [55]
- [56]
- [57]
- [58]
- [59]
- [60]
- [61]
- [62]
- [63]
- [64]
- [65]
- [66]
- [67]
- [68]
- [69]
- [70]
- [71]
- [72]
- [73]
- [74]
- [75]
- [76]
- [77]
- [78]
- [79]
- [80]
- [81]
- [82]
- [83]
- [84]
- [85]
- [86]
- [87]
- [88]
- [89]
- [90]
- [91]
- [92]
- [93]
- [94]
- [95]
- [96]
- [97]
- [98]
- [99]
- [100]
- [101]
- [102]
- [103]
- [104]
- [105]
- [106]
- [107]
- [108]
- [109]
- [110]
- [111]
- [112]
- [113]
- [114]
- [115]
- [116]
- [117]
- [118]
- [119]
- [120]
- [121]
- [122]
- [123]
- [124]
- [125]
- [126]
- [127]
- [128]
- [129]
- [130]
- [131]
- [132]
- [133]
- [134]
- [135]
- [136]
- [137]
- [138]
- [139]
- [140]
- [141]
- [142]
- [143]
- [144]
- [145]
- [146]
- [147]
- [148]
- [149]
- [150]
- [151]
- [152]
- [153]
- [154]
- [155]
- [156]
- [157]
- [158]
- [159]
- [160]
- [161]
- [162]
- [163]
- [164]
- [165]
- [166]
- [167]
- [168]
- [169]
- [170]
- [171]
- [172]
- [173]
- [174]
- [175]
- [176]
- [177]
- [178]
- [179]
- [180]
- [181]
- [182]
- [183]
- [184]
- [185]
- [186]
- [187]
- [188]
- [189]
- [190]
- [191]
- [192]
- [193]
- [194]